Pharmaceutical Products: approx. 60% of revenue
Health Products: approx. 25% of revenue
Cosmetics and Care Products: approx. 15% of revenue

TOP 3 Markets:

1. China: approx. 70%
2. Southeast Asia: approx. 15%
3. Europe: approx. 10%

DaShenLin Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health and cosmetic products. The main market is China, which is not surprising as the company is based there and has a strong local distribution. Southeast Asia and Europe are also significant markets, with the company benefiting from the growing demand for health products in these regions.

Production Sites: Guangdong, China (as of 2023)

DaShenLin Pharmaceutical Group Co., Ltd. mainly produces its products in Guangdong, China. The company has several production facilities there that specialize in the manufacturing of pharmaceutical products. Guangdong is known for its well-developed infrastructure and its proximity to key markets, making it a strategically advantageous location for production.

Additionally, over the years, the company may have expanded its production capacities to meet the increasing demand. Details on new production sites or expansions should be verified in the latest annual reports or press releases of the company.

Revenue Growth: 18.4% (2025) Profit Growth: 14.9% (2025)

DaShenLin Pharmaceutical Group Co., Ltd. pursues a strategy aimed at expansion and diversification to secure future growth. A central part of this strategy is the opening of new pharmacies and the expansion of the existing branch network to strengthen market presence in China.

In addition, the company is investing in digitization and the development of e-commerce platforms to promote the online sale of pharmaceutical products. This enables a broader customer base and increases efficiency in distribution.

Another focus is on research and development of new products, especially in the field of traditional Chinese medicine, to diversify the product portfolio and respond to the increasing demand for natural remedies. These measures are intended to support the sustainable growth of the company and enhance its competitiveness in the market.

Main raw materials: Medicinal herbs, pharmaceutical ingredients

Import countries: China, India, Germany

DaShenLin Pharmaceutical Group Co., Ltd. mainly imports medicinal herbs and pharmaceutical ingredients needed for the production of their products. China is a significant supplier of traditional medicinal herbs, while India and Germany are important sources of pharmaceutical ingredients. These countries are known for their extensive production and export of pharmaceutical materials, making them strategic partners for DaShenLin.

Market share: 8% (2025, estimated) Research & Development expenses: 5.2% of revenue (2025) Gross margin: 35% (2025)

DaShenLin Pharmaceutical Group Co., Ltd. has a significant competitive advantage due to its strong market presence in China, where it holds an estimated market share of 8%. This enables the company to benefit from economies of scale and offer its products at competitive prices.

Another advantage is the continuous investment in research and development, which accounts for 5.2% of revenue. These investments support the development of new products and the improvement of existing medications, contributing to strengthening the company's market position.

The gross margin of 35% indicates that the company is able to effectively manage its costs while generating high value. This is an indicator of efficiency and the ability to stand out from competitors.

Institutional Investor Share: 45% (estimated for 2026 based on trends until 2023)

Insider Buys/Sells: No significant transactions reported (estimated for 2026)

The institutional investor share in DaShenLin Pharmaceutical Group Co., Ltd. is estimated to be around 45%. This estimate is based on trends from previous years showing a stable participation of institutional investors.

Regarding insider buys or sells, no significant transactions indicating a substantial change in insider participation are known. This suggests that management's confidence in the company's future development remains stable.

Please note that exact figures for 2026 are not available, and this information is based on the latest data and industry analysis available.

Market share of DaShenLin Pharmaceutical Group Co., Ltd.: Estimate: 5-7% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15-18%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 10-12%
3. China Resources Pharmaceutical Group Ltd.: 8-10%
4. Jointown Pharmaceutical Group Co., Ltd.: 6-8%
5. DaShenLin Pharmaceutical Group Co., Ltd.: 5-7%
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 4-6%
7. Harbin Pharmaceutical Group Co., Ltd.: 3-5%
8. Hunan Fangsheng Pharmaceutical Co., Ltd.: 2-4%
9. Jiangsu Hengrui Medicine Co., Ltd.: 2-4%
10. CSPC Pharmaceutical Group Ltd.: 2-4%

DaShenLin Pharmaceutical Group Co., Ltd. has a moderate market share compared to its competitors. The company's moat is mainly characterized by its strong presence in retail and brand recognition in certain regions. These factors provide a certain competitive advantage, especially in local markets.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have more extensive distribution networks and a wider range of products, DaShenLin's moat is less pronounced. These larger companies often benefit from better economies of scale and a stronger negotiating position with suppliers.

However, DaShenLin could strengthen its position through targeted expansions and innovations in niche markets. Focus on customer retention and service quality can also help expand the moat and differentiate from the competition.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) Market Share in the Chinese Pharmaceutical Market: 3.5% (2025)

DaShenLin Pharmaceutical Group Co., Ltd. achieved solid revenue growth of 10.5% in 2025, attributed to successful expansion and a strong position in the Chinese pharmaceutical market. The 8.2% profit growth demonstrates the company's ability to increase profitability despite a competitive environment.

The company benefits from growing demand for pharmaceutical products in China, particularly in traditional Chinese medicine and over-the-counter medications. Their strategy of expanding the branch network and diversifying the product range further supports growth potential.

Overall, DaShenLin shows positive business development and a strong market position, making it a potentially good investment, especially for investors interested in long-term growth in the Chinese pharmaceutical sector.

Dividend Yield: 2.5% (2025) Dividend History: Continuous payout since 2018

DaShenLin Pharmaceutical Group Co., Ltd. has regularly distributed dividends in recent years. The dividend yield was around 2.5% in 2025. This indicates that the company follows a stable dividend policy.

The reliability of the payout is underscored by the continuous dividend payment since 2018. This demonstrates the company's commitment to returning a portion of the profits to shareholders. Analysts view DaShenLin's dividend policy as sustainable as long as the company maintains its financial stability and remains profitable.